Abstract
Aim
The aim of this study was to determine the frequency of varicella zoster virus (VZV) infection in patients undergoing allogeneic haematopoietic stem cell transplant (allo-HSCT) in a single hospital.
Method
This retrospective study included all patients who underwent allo-HSCT during the period of April 2004–December 2014 in The Aga Khan University Hospital in Pakistan. Medical records were reviewed to determine the proportion of allo-HSCT patients who developed VZV infection.
Results
The study included 133 patients, of whom 93 (70 %) were male and 40 (30 %) were female. The median patient age was 20 years, and all patients received prophylactic antiviral therapy. After transplant, ten patients developed VZV infection, with a median patient age of 16.5 years, and a median time to VZV infection of 302 days (range 102–805 days). The most common underlying diagnosis was aplastic anaemia. Of the ten affected patients, nine responded to therapeutic doses of aciclovir or valaciclovir, and one was lost to follow up.
Conclusion
In our study, the frequency of VZV infection following allo-HSCT was lower than that commonly reported in the international literature.
References
Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood. 2002;100(3):761–7.
Kruger WH, Bohlius J, Cornely OA, et al. Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the infectious diseases working party (AGIHO) of the german society of haematology and oncology. Ann Oncol. 2005;16(8):1381–90.
Koc Y, Miller KB, Schenkein DP, et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant. 2000;6(1):44–9.
Atkinson K, Meyers JD, Storb R, et al. Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia. Transplantation. 1980;29(1):47–50.
Ljungman P, Wilczek H, Gahrton G, et al. Long-term prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transplant. 1986;1(2):185–92.
Selby PJ, Powles RL, Easton D, et al. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. Br J Cancer. 1989;59(3):434–8.
Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2000;6(6a):659–713.
Schuchter LM, Wingard JR, Piantadosi S, et al. Herpes zoster infection after autologous bone marrow transplantation. Blood. 1989;74(4):1424–7.
Han CS, Miller W, Haake R, et al. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant. 1994;13(3):277–83.
Arvin AM, Gershon AA. Live attenuated varicella vaccine. Annu Rev Microbiol. 1996;50:59–100.
Tzeng CH, Liu JH, Fan S, et al. Varicella zoster virus infection after allogeneic or autologous hemopoietic stem cell transplantation. J Formos Med Assoc. 1995;94(6):313–7.
Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–238.
Locksley RM, Flournoy N, Sullivan KM, et al. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis. 1985;152(6):1172–81.
Ullah K, Raza S, Ahmed P, et al. Post-transplant infections: single center experience from the developing world. Int J Infect Dis. 2008;12(2):203–14.
Kawasaki H, Takayama J, Ohira M. Herpes zoster infection after bone marrow transplantation in children. J Pediatr. 1996;128(3):353–6.
Leung TF, Chik KW, Li CK, et al. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation. Bone Marrow Transplant. 2000;25(2):167–72.
Berman JN, Wang M, Berry W, et al. Herpes zoster infection in the post-hematopoietic stem cell transplant pediatric population may be preceded by transaminitis: an institutional experience. Bone Marrow Transplant. 2006;37(1):73–80.
Meyers JD, Wade JC, Shepp DH, et al. Acyclovir treatment of varicella-zoster virus infection in the compromised host. Transplantation. 1984;37(6):571–4.
Serota FT, Starr SE, Bryan CK, et al. Acyclovir treatment of herpes zoster infections: use in children undergoing bone marrow transplantation. JAMA. 1982;247(15):2132–5.
Onozawa M, Hashino S, Haseyama Y, et al. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group. Biol Blood Marrow Transplant. 2009;15(6):724–9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No sources of funding were used to conduct the study or prepare this report.
Conflict of interest
M.U. Shaikh, H. Haji, N. Ali and S.N. Adil declare that they have no conflicts of interest relevant to the content of this manuscript.
Ethical approval
This study was granted exemption for ethical approval from the institutional ethical review committee (3843-Pat-ERC-15).
Rights and permissions
About this article
Cite this article
Ali, N., Shaikh, M.U., Haji, H. et al. Frequency of varicella zoster virus infection in allogeneic stem cell transplant patients: case series from a single centre. Drugs Ther Perspect 32, 72–75 (2016). https://doi.org/10.1007/s40267-015-0264-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-015-0264-3